Literature DB >> 2146363

In vitro expansion of CD3/TCR- human thymocyte populations that selectively lack CD3 delta gene expression: a phenotypic and functional analysis.

A Poggi1, R Biassoni, N Pella, F Paolieri, R Bellomo, A Bertolini, L Moretta, M C Mingari.   

Abstract

Highly purified CD1-3-4-8- human thymocytes were obtained by panning techniques combined with cell depletion with antibody-coated magnetic beads. Most of these cells expressed cytoplasmic CD3 antigen, as assessed by mAbs known to react with the CD3 epsilon chain. After culture with low doses of PMA (0.5 ng/ml) and subsequent addition (at 24 h) of recombinant interleukin 2 (rIL-2; 100 U/ml) cells underwent extensive proliferation (40-60-fold of the initial cell input after 2 wk). The majority of the proliferating cells were CD3-TCR-. The remaining cells (5-40%) were represented by CD3+ TCR gamma/delta+ (BB3- A13+) cells. Further removal of CD3+ TCR-gamma/delta+ cells resulted in highly purified CD3- populations that further proliferated in culture with no substantial phenotypic changes. When CD3+ thymocytes were cultured under the same experimental conditions, only CD3+ TCR-alpha/beta+ cells could be detected, thus indicating that PMA did not affect the surface expression of the CD3/TCR complex, but rather induced preferential growth of CD3- thymocytes. Surface marker analysis of cultured CD3- thymocytes showed that they were homogeneously CD7+, whereas low proportions of cells expressed CD2 and CD8 antigens. Among the natural killer (NK) cell markers, CD56 was highly expressed by all cells, whereas CD16, CD57, CD11b, NKH2, and GL183 were absent. Importantly, these cells were different from peripheral NK cells, as 80-95% of them expressed cytoplasmic CD3 antigen. Functional analysis revealed a strong cytolytic activity against both NK-sensitive (K562) and NK-resistant (M14, Daudi) human target cells. In a redirected killing assay against the Fc gamma R+ P815 cells, mAbs specific for triggering molecules including CD3, CD2, and CD16 failed to augment target cell lysis, while a strong cytolytic effect was induced by PHA. In addition, PHA alone or in combination with PMA induced tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) (but not IL-2) production by CD3- thymocytes. Cloning of fresh CD1-3-4-8-thymocytes in the presence of PMA and rIL-2 resulted in CD3-CD56+ clones that displayed a pattern of cytolytic activity and lymphokine production similar to that of the polyclonal populations. Northern blot analysis of transcripts coding for CD3/TCR molecules revealed the presence of CD3 zeta, epsilon, and gamma transcripts, while CD3 delta was undetectable. Mature transcripts for both gamma and delta TCR chains could be detected, whereas no TCR-alpha mRNA and only a truncated (1.0 kb) form of TCR-beta mRNA were revealed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146363      PMCID: PMC2188658          DOI: 10.1084/jem.172.5.1409

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

Review 1.  Early events in T-cell maturation.

Authors:  B Adkins; C Mueller; C Y Okada; R A Reichert; I L Weissman; G J Spangrude
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

2.  Developmental regulation of T-cell receptor gene expression.

Authors:  D H Raulet; R D Garman; H Saito; S Tonegawa
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

3.  CD3+ WT31- peripheral T lymphocytes lack T44 (CD28), a surface molecule involved in activation of T cells bearing the alpha/beta heterodimer.

Authors:  A Poggi; C Bottino; M R Zocchi; G Pantaleo; E Ciccone; C Mingari; L Moretta; A Moretta
Journal:  Eur J Immunol       Date:  1987-07       Impact factor: 5.532

4.  CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene.

Authors:  R Biassoni; S Ferrini; I Prigione; A Moretta; E O Long
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

5.  Sequence and organization of the human T cell delta chain gene.

Authors:  Y Takihara; E Champagne; H Griesser; N Kimura; D Tkachuk; J Reimann; A Okada; F W Alt; L Chess; M Minden
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

6.  Transient expression of IL-2 receptor precedes the differentiation of immature thymocytes.

Authors:  R P Shimonkevitz; L A Husmann; M J Bevan; I N Crispe
Journal:  Nature       Date:  1987 Sep 10-16       Impact factor: 49.962

7.  Repertoire of the human T cell gamma genes: high frequency of nonfunctional transcripts in thymus and mature T cells.

Authors:  Y Yoshikai; B Toyonaga; Y Koga; N Kimura; H Griesser; T W Mak
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

8.  Involvement of the interleukin 2 pathway in the rearrangement and expression of both alpha/beta and gamma/delta T cell receptor genes in human T cell precursors.

Authors:  M L Toribio; A de la Hera; J Borst; M A Marcos; C Márquez; J M Alonso; A Bárcena; C Martínez
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s).

Authors:  E Ciccone; S Ferrini; C Bottino; O Viale; I Prigione; G Pantaleo; G Tambussi; A Moretta; L Moretta
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

10.  Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor.

Authors:  C Bottino; G Tambussi; S Ferrini; E Ciccone; P Varese; M C Mingari; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

View more
  6 in total

1.  Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells.

Authors:  Chiara Romagnani; Gabriella Pietra; Michela Falco; Enrico Millo; Paola Mazzarino; Roberto Biassoni; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-07       Impact factor: 11.205

2.  HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes.

Authors:  Gabriella Pietra; Chiara Romagnani; Paola Mazzarino; Michela Falco; Enrico Millo; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

3.  Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells.

Authors:  Susan L Heatley; Gabriella Pietra; Jie Lin; Jacqueline M L Widjaja; Christopher M Harpur; Sue Lester; Jamie Rossjohn; Jeff Szer; Anthony Schwarer; Kenneth Bradstock; Peter G Bardy; Maria Cristina Mingari; Lorenzo Moretta; Lucy C Sullivan; Andrew G Brooks
Journal:  J Biol Chem       Date:  2013-01-18       Impact factor: 5.157

4.  In vitro proliferation and cloning of CD3- CD16+ cells from human thymocyte precursors.

Authors:  M C Mingari; A Poggi; R Biassoni; R Bellomo; E Ciccone; N Pella; L Morelli; S Verdiani; A Moretta; L Moretta
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

5.  CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.

Authors:  A Moretta; A Poggi; D Pende; G Tripodi; A M Orengo; N Pella; R Augugliaro; C Bottino; E Ciccone; L Moretta
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

6.  Precursors of CD3+CD4+CD8+ cells in the human thymus are defined by expression of CD34. Delineation of early events in human thymic development.

Authors:  A Galy; S Verma; A Bárcena; H Spits
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.